FAQs

The 7th Supply Chain & Logistics Summit for Cell & Gene Therapy summit is a senior-level forum dedicated to addressing end-to-end supply chain challenges for Advanced Therapies. The program outlines real-world strategies for commercial-scale readiness, regulatory navigation, risk mitigation, and the operationalization of Chain of Identity (COI) and Chain of Custody (COC) at a global scale.

This event is designed to facilitate peer-to-peer discussion on solving systemic bottlenecks in CGT logistics and distribution.

This summit is tailored for senior decision-makers, including:

• VP/Head of Supply Chain
• Technical Operations and Manufacturing Leaders
• Global Distribution and Logistics Directors
• Quality and Regulatory Executives
• Specialist CGT logistics and technology providers

Attendance is most relevant for organisations actively scaling autologous or allogeneic therapy programs and seeking to strengthen global supply chain resilience.

Sessions examine the logistical frameworks required for autologous and allogeneic therapy patient access, including:

• Vein-to-vein orchestration
• Multi-site manufacturing coordination
• Cryogenic transport infrastructure
• Real-time data visibility platforms
• Decentralized manufacturing logistics

The focus is on operational scalability, capacity constraints, and compressing timelines, whilst maintaining regulatory compliance and good manufacturing practices.

The summit addresses applicable solutions to:

• Temperature management for product viability
• Cross-border customs and regulatory disruption
• Single-point-of-failure instances
• Digital redundancy and data integrity
• Contingency planning for global distribution networks

Emphasis is placed on resilient frameworks suitable for commercial-stage CGT portfolios.

Global regulatory divergence remains a key constraint in Advanced Therapies logistics. This summit examines:

• Regulatory alignment strategies across diverse regions
• Import/export licensing challenges
• Documentation harmonization across jurisdictions
• Real world case studies of expansion into challenging markets
• Compliant transport validation

Discussion is focused on practical implementation at a global level.

Digital enablement is central to managing chain of identity, custody, and condition monitoring. The summit explores:

• End-to-end digital orchestration platforms
• Real-time shipment monitoring and analytics
• Advanced traceability frameworks
• Data integration across manufacturing and logistics partners
• Cybersecurity considerations in CGT data ecosystems

Sessions prioritise interoperability and look toward digitalization benefits within advanced therapies supply.

Commercial readiness discussions centre on:

• The transition from clinic to commercial readiness
• Capacity planning for increased patient access
• Forging strategic partnerships to enhance supply
• Cost-of-goods optimisation
• Scalable cryogenic infrastructure

The objective is to support sustainable commercial supply chain architectures.

The summit is structured to enable targeted networking between:

• Biopharma sponsors
• Specialist cold chain and cryogenic providers
• Blood banks and apheresis sites
• Digital tracking technology companies
• Regulatory and quality consultants
• Global logistics integrators (CDMO)

The environment is curated to facilitate partnership discussions between key decision makers and crucial solution providers.

Unlike general pharmaceutical logistics events, this summit is exclusively focused on the unique operational, regulatory, and technical complexities of cell and gene therapy supply chains.

Content assumes familiarity with CGT fundamentals and prioritises advanced discussion on decentralized manufacturing, regulatory management, ultra-low temperature logistics, and integrated data visibility at scale.

As CGT portfolios expand globally, supply chain architecture has become a board-level concern. Decisions relating to global distribution partnerships, regulatory alignment, and the race toward digitalization, directly influence commercial viability and patient access.

Executive participation enables alignment between commercial goals and operational execution, ensuring supply chain design has resilience embedded for long-term portfolio expansion.